Triamcinolone

Corticosteroid — ALIMENTARY TRACT AND METABOLISM

Key facts

Triamcinolone is an ofm drug in the Corticosteroid class catalogued in DrugCentral. It was first approved by the FDA in 1957. Its mechanism of action is classified as Corticosteroid Hormone Receptor Agonists. DrugCentral lists 3 molecular targets, including NR3C1, ANXA1 and PGR. Recorded indications include Acquired thrombocytopenia, Acute lymphoid leukemia, Adrenal cortical hypofunction and Adrenogenital disorder.

• Approval status: ofm (first approved 1957 by the FDA).
• Drug class: Corticosteroid.
• Mechanism of action: Corticosteroid Hormone Receptor Agonists.
• Molecular targets: NR3C1, ANXA1 and PGR (3 listed in DrugCentral).
• Indications: Acquired thrombocytopenia, Acute lymphoid leukemia, Adrenal cortical hypofunction, Adrenogenital disorder and Allergic rhinitis and others.
• ATC code: A01AC01 (Corticosteroids for local oral treatment).
• Molecular formula: C21H27FO6; molecular weight 394.44 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (88)

• Acquired thrombocytopenia
• Acute lymphoid leukemia
• Adrenal cortical hypofunction
• Adrenogenital disorder
• Allergic rhinitis
• Allergic Rhinitis Prevention
• Alopecia areata
• Angioedema
• Ankylosing spondylitis
• Aphthous ulcer of mouth
• Articular gout
• Aspiration pneumonitis
• Asthma
• Asthma management
• Atopic dermatitis
• Autoimmune disease
• Autoimmune hemolytic anemia
• Berylliosis
• Bursitis
• Candidiasis of skin
• Cerebral edema
• Chronic Non-Allergic Rhinitis
• Congenital adrenal hyperplasia
• Congenital hypoplastic anemia
• Contact dermatitis
• Crohn's disease
• Cystic Aponeurosis Tumor
• Dermatitis herpetiformis
• Diagnostic Test for Cushing's Syndrome
• Discoid lupus erythematosus
• + 58 more

Off-label uses (3)

• Bronchitis
• Carditis
• Celiac disease

Contraindications (9)

• Acute tuberculosis
• Anastomosis of intestine
• Arginase deficiency
• Arginosuccinate Lyase Deficiency
• Atrophoderma
• Avascular necrosis of bone
• Bacterial infectious disease
• Bilateral cataracts
• Candidiasis of mouth

Mechanism & targets

• Mechanism of action (MoA): Corticosteroid Hormone Receptor Agonists
• Established pharmacologic class: Corticosteroid

Molecular targets (3)

Target	Gene	Action	Activity
Glucocorticoid receptor	NR3C1	agonist	Ki 7.58
Annexin A1	ANXA1	unknown	—
Progesterone receptor	PGR	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1957-12-03	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
A01AC01	ALIMENTARY TRACT AND METABOLISM › STOMATOLOGICAL PREPARATIONS › STOMATOLOGICAL PREPARATIONS › Corticosteroids for local oral treatment
C05AA12	CARDIOVASCULAR SYSTEM › VASOPROTECTIVES › AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE › Corticosteroids
D07AB09	DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, PLAIN › Corticosteroids, moderately potent (group II)
D07BB03	DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS › Corticosteroids, moderately potent, combinations with antiseptics
D07CB01	DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS › Corticosteroids, moderately potent, combinations with antibiotics
D07XB02	DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, OTHER COMBINATIONS › Corticosteroids, moderately potent, other combinations
H02AB08	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › CORTICOSTEROIDS FOR SYSTEMIC USE › CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN › Glucocorticoids
R01AD11	RESPIRATORY SYSTEM › NASAL PREPARATIONS › DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE › Corticosteroids
R03BA06	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS › Glucocorticoids
S01BA05	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS › Corticosteroids, plain

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug ineffective	1431.4
Dermatitis atopic	1177.7
Psoriasis	743.3
Adrenal insufficiency	693.3
Skin exfoliation	530.8
Therapeutic product effect incomplete	506.0
Product use in unapproved indication	504.1
Polyarthritis	501.6
Human antichimeric antibody positive	414.2
Body height below normal	410.4
Joint destruction	399.5
Obesity	365.6

Chemical structure

• Molecular formula: C₂₁H₂₇FO₆
• Molecular weight: 394.44 g/mol
• CAS number: 124-94-7
• InChIKey: GFNANZIMVAIWHM-OBYCQNJPSA-N
• PubChem CID: 31307

C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Triamcinolone used for?

DrugCentral lists the following indications for Triamcinolone: Acquired thrombocytopenia, Acute lymphoid leukemia, Adrenal cortical hypofunction, Adrenogenital disorder, Allergic rhinitis, Allergic Rhinitis Prevention, Alopecia areata and Angioedema and others.

How does Triamcinolone work?

Triamcinolone is classified as Corticosteroid Hormone Receptor Agonists; its molecular targets in DrugCentral include NR3C1 (agonist), ANXA1 and PGR.

When was Triamcinolone first approved?

Triamcinolone was first approved by the FDA in 1957.

What drug class does Triamcinolone belong to?

Triamcinolone is in the Corticosteroid class.

What is the chemical formula of Triamcinolone?

Triamcinolone has the molecular formula C21H27FO6 and a molecular weight of 394.44 g/mol.

Sources

• DrugCentral drug card 2725 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1451 — compound record and bioactivity
• PubChem CID 31307 — chemical identifiers
• DrugBank DB00620 — drug record
• FDA UNII 1ZK20VI6TY — substance identity
• DailyMed: FDA labels for Triamcinolone — current prescribing information (label search)
• UniProt P04150 (NR3C1) — target protein
• UniProt P04083 (ANXA1) — target protein
• UniProt P06401 (PGR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.